Showing 6171-6180 of 9536 results for "".
- Efficacy Data for LaViv Now Publishedhttps://practicaldermatology.com/news/20120418-efficacy_data_for_laviv_now_published/2459822/Data demonstrating that LaViv (azficel-T, Fibrocell Science, Inc.) is effective for the aesthetic improvement of moderate to severe smile lines are now published online in Dermatologic Surgery. The combined results of two identically-designed, Phase III, multi-
- Botox Reaches 10-Year Milestone in Aestheticshttps://practicaldermatology.com/news/20120416-botox_reaches_10-year_milestone_in_aesthetics/2459824/Allergan, Inc. marked the 10-year anniversary of the FDA approval of Botox Cosmetic (onabotulinumtoxinA) to improve the look of moderate to severe frown lines between the eyebrows in patients age 18-65.In the decade since Botox Cos
- Lumenis Unveiling New Laser Capability at ASLMShttps://practicaldermatology.com/news/20120413-lumenis_unveiling_new_laser_capability_at_aslms/2459826/Lumenis will unveil UltraPulse's new SCAAR FX CO2 laser treatment capability at the American Society for Laser Medicine and Surgery (ASLMS) annual meeting in Kissimmee, FL. Using up to 150mJoules per pulse, the high energy impact and precision o
- Warning for Blood Clot Risk Added to Drospirenone OCPshttps://practicaldermatology.com/news/20120411-warning_for_blood_clot_risk_added_to_drospirenone_ocps/2459827/The U.S. Food and Drug Administration (FDA) has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills. Drospirenone is a synthetic version of the female hormone, progesterone, also referred t
- Vichy Partners With timeRAZOR for Free iPhone, Android Apphttps://practicaldermatology.com/news/20120404-vichy_partners_with_timerazor_for_free_iphone_android_app/2459828/With the new timeRAZOR app, Vichy and timeRAZOR help keep users in the know on events occurring close to where they work, live, or plan to be. timeRAZOR pairs technologic components like geolocation with its own Massive Event Selection Engine, i
- Rosacea Awareness: 16 Million Americans Affected, Stressedhttps://practicaldermatology.com/news/20120402-rosacea_awareness_16_million_americans_affected_stressed/2459829/More than 90 percent of more than 1,200 respondents with rosacea said they suffered some form of physical pain from rosacea, according to a new survey by the National Rosacea Society (NRS). With April designated as Rosacea Awareness Month, the NRS strives to educate the public on the effects of rosa
- Olympic Swimmer Dara Torres Named Brand Ambassador for AmLactinhttps://practicaldermatology.com/news/20120329-olympic_swimmer_dara_torres_named_brand_ambassador_for_amlactin/2459830/AmLactin Alpha-Hydroxy Skin Care is kicking off the new “Ultra Skin Performance” campaign (Upsher-Smith Laboratories, Inc.) and has named 12-time Olympic medalist Dara Torres its first-ever brand ambassador . The “Ultra Skin Performance” campaign educates women of all ages about the internal and ext
- La Roche-Posay Launches Mobile “Dermatologist By Your Side” Educationhttps://practicaldermatology.com/news/20120320-la_roche-posay_launches_mobile_dermatologist_by_your_side_education/2459835/When patients want advice on skin care products in the pharmacy or anywhere, they can dial **DERM from a mobile phone. An automated text response leads them to a dedicated YouTube.com site, featuring educational videos from dermatologists Kavita Mariwala, MD and Shirley Chi, MD. The program from
- Skinvisible Granted Patent for UVA Absorberhttps://practicaldermatology.com/news/20120320-skinvisible_granted_patent_for_uva_absorber/2459836/Skinvisible Pharmaceuticals, Inc. has been granted a new patent for its UVA sunscreen absorber. Skinvisible's new formulation with avobenzone provides eight hours of photostability, an advantage for those who spend many hours in the sun. The ingredi
- Galderma Completes Phase 3 Rosacea Erythema Studyhttps://practicaldermatology.com/news/20120320-galderma_completes_of_phase_3_rosacea_erythema_study/2459839/Galderma Laboratories announced the completion of two independent Phase 3 clinical trials that evaluated the safety and efficacy of CD07805/47, a proprietary topical gel under investigation in patients with moderate to severe facial erythema of